Belantamab Mafodotin-Blmf: Clinical Trials

3 recruiting, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 6 Phase 2, 4 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	6	Recruiting 3, Active not recruiting 1, Not yet recruiting 1, Unknown 1
Phase 1	4	Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1

Follow Belantamab Mafodotin-Blmf: new trials by email Literature Review of Belantamab Mafodotin-Blmf trials Research Report on Belantamab Mafodotin-Blmf

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant Belantamab Mafodotin, Lenalidomide - Plasma Cell Myeloma	Phase 2	Active not recruiting	Roswell Park Cancer Institute	4	2024-08-19	2026-10-16
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate - Recurrent Multiple Myeloma, Refractory Multiple Myeloma	Phase 2	Recruiting	Mayo Clinic	62	2024-01-04	2026-07-14
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone - Multiple Myeloma, Neoplasms	Phase 1 / Phase 2	Recruiting	Hellenic Society of Hematology	36	2023-07-14	2023-10-24
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide - Multiple Myeloma, Multiple Myeloma in Relapse	Phase 1 / Phase 2	Not yet recruiting	Hellenic Society of Hematology	48	2022-10-20	2022-10-17
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma Belantamab Mafodotin, Dexamethasone, Pomalidomide - Plasma Cell Myeloma	Phase 2	Recruiting	Emory University	34	2022-07-21	2026-09-03
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide - Multiple Myeloma, Neoplasms	Phase 1 / Phase 2	Unknown	Hellenic Society of Hematology	36	2022-04-13	2023-12-01
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma Belantamab Mafodotin, Daratumumab, Dexamethasone - Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma	Phase 1	Terminated	Mayo Clinic	5	2021-06-03	2025-05-18

Conditions studied

Multiple Myeloma (7)  ·  Blood Protein Disorders (3)  ·  Corneal Diseases (3)  ·  Hematologic Diseases (3)  ·  Neoplasms (3)  ·  Neoplasms, Plasma Cell (3)  ·  Paraproteinemias (3)

Sponsors

Hellenic Society of Hematology (3)  ·  Mayo Clinic (2)  ·  Emory University (1)  ·  Roswell Park Cancer Institute (1)

Countries

United States (4)  ·  Greece (2)

Top investigators

Evangelos Terpos, Prof (3)  ·  Ajay K. Nooka, MD,MPH,FACP (1)  ·  Jens Hillengass (1)  ·  Ricardo D. Parrondo, M.D. (1)  ·  Shaji K. Kumar, M.D. (1)

Results publications

PMID 34182226, PMID 35285981

NIH funding

P30CA138292 (1)